Multiomics, pharmacogenomic, and structural characterization of NCCRP1 as a candidate therapeutic target in ovarian cancer.

Dahlak Daniel Solomon Yung-Kuo Lee Sachin Kumar Kai-Fu Chang Chung-Hsien Lin Ching-Chung Ko Ngoc Uyen Nhi Nguyen Do Thi Minh Xuan Neethu Palekkode Chi Wang Hui-Ru Lin

Sep 2026 · Naunyn-Schmiedeberg's Archives of Pharmacology · 0 citations · 37 references

Medicine

TL;DR

The utility of integrating multiomics, pharmacogenomic, structural, and single-cell approaches for therapeutic target discovery and prioritization in cancer is demonstrated.

DOI PubMed Semantic Scholar

View source

Similar papers

Open access Sep 2026

Integrated multi-omics, spatial transcriptomics, and functional studies implicate MDK as a mediator of cisplatin-response phenotypes in ovarian cancer

Platinum resistance remains a central barrier to durable disease control in ovarian cancer. In this study, we integrated an ovarian cancer susceptibility GWAS, multi-omics profiling (CPTAC/TCGA), and spatial-single-cell transcriptomics to identify novel therapeutic targets. Cross-platform prioritization nominated m...

Feng Jin, Fang-Xin Li, Xiao-Ao Pang et al. · Cell Biology and Toxicology · 0 citations

Open access Oct 2026

Pan-cancer and experimental analyses reveal TTC39B as a suppressor of cell proliferation in clear cell renal cell carcinoma

Tetratricopeptide repeat domain protein 39B (TTC39B) is a lipid metabolism–related gene recently implicated in cholesterol regulation. However, its clinical and biological relevance in human cancers remains undefined. Based on multi-omics data from the Cancer Genome Atlas (TCGA) pan-cancer dataset represen...

Hui-Juan Yi, Yan Wang, Chen-Hao Zhao et al. · BMC Medical Genomics · 0 citations

Open access Oct 2026

Multi-omics bioinformatic screening identifies PFDN2 as an obesity-correlated molecular target of triple-negative breast cancer

Triple-negative breast cancer (TNBC) is characterized by high malignancy, poor prognosis and a lack of specific therapeutic targets. Obesity acts as a major risk factor facilitating TNBC progression, while the molecular features underlying their correlation remain poorly systematically characterized. In this study, w...

Hui-Min Liu, Jun-Peng Huang, Qing-Yu Song · Discover Oncology · 0 citations

Open access Oct 2026

Integrative Multi-Omics Reveals TSPAN13 as a Candidate Epithelial–Mesenchymal Transition-Associated Regulator in Prostate Cancer

Background: Prostate cancer (PCa) is a malignancy with high metastatic potential and poor prognosis, underscoring the urgent need for effective biomarkers and therapeutic targets to improve clinical management. Methods: An integrative multi-omics analysis combined with machine learning algorithms was performed to ident...

Shuo Lu, Hou-He Li, Zi-Xiao Zhang et al. · Biomedicines · 0 citations

Open access Sep 2026

Targeting the DNHD1-HDAC6 axis inactivates prostate cancer cell aggressiveness in vitro, suggesting potential therapeutic vulnerability

It is implied that in prostate cancer, the DNHD1-HDAC6 axis, a novel regulatory pathway, promotes aggressiveness and that HDAC6 is a targetable mediator of DNHD1-driven malignancy.

An-Nie-On-Nei Lee, Chia-Chang Wu, Su-Wei Hu et al. · Oncology Report · 0 citations

Open access Sep 2026

Multi-omics characterization of P2RX4-associated immune microenvironment features and proof-of-concept observations of peritumoral radiomic phenotypes in TNBC

In the analyzed TNBC datasets, P2RX4 expression was associated with CD163 expression and hypoxia-related transcriptional features, and across transcriptomic analyses, P2RX4 expression was positively associated with CD163 expression and hypoxia-related transcriptional features.

Yi-Fei Meng, Yong-Qiu Zhu, Yue Zhang et al. · BMC Medical Imaging · 0 citations